Login Register Cart 0
Research Article

Molecular Docking Study of Active Diazenyl Scaffolds as Inhibitors of Essential Targets Towards Antimicrobial Drug Discovery

Author(s): Harmeet Kaur, Sudhir Gahlawat, Jasbir Singh and Balasubramanian Narasimhan*

Volume 20, Issue 15, 2019

Page: [1587 - 1602] Pages: 16

DOI: 10.2174/1389450120666190618122359

Price: $65

Abstract

Background: The diazenyl compounds (-N=N- linkage) have been reported to have antimicrobial activity. In modern drug discovery, the drug-receptor interactions are generally explored by the molecular docking studies.

Materials and Methods: Three categories of diazenyl scaffolds were screened for the docking studies to explore the binding mechanism of interaction with various microbial targets. The diazenyl Schiff bases (SBN-20, SBN-21, SBN-25, SBN-33, SBN-39, SBN-40 and SBN-42), naphthol pharmacophore based diazenyl Schiff bases (NS-2, NS-8, NS-12, NS-15, NS-21, and NS-23), morpholine based diazenyl chalcones (MD-6, MD-9, MD-14, MD-16, MD-20, and MD-21) were docked against various bacterial and fungal proteins in comparison with different standard drugs. Further, the drug likeliness and ADME properties of these molecules were predicted by QikProp module of the Schrodinger software.

Results: Most of the derivatives had shown less docking scores and binding energies towards bacterial proteins, such as dihydropteroate synthase (PDB:2VEG), glucosamine-6-phosphate synthase (PDB:2VF5), dihydrofolate reductase (PDB:3SRW) in comparison with the standard drugs. The naphthol based diazenyl Schiff bases NS-21 and NS-23 were predicted to act on the cytochrome P450 sterol 14-alpha-demethylase (CYP51) (PDB:5FSA) involved in sterol biosynthesis, an essential target for antifungal drugs. The derivative MD-6, NS-2, NS-21, and NS-23 had shown high docking scores against bacterial DNA topoisomerase (PDB:3TTZ) in comparison with the standard drug ciprofloxacin. Further, most of the synthesized derivatives had shown drug like characters.

Conclusion: Hence, these compounds can be developed as novel antibacterial agents as potent DNA topoisomerase inhibitors and antifungal agents as CYP51 inhibitors.

Keywords: Diazenyl, morpholine, naphthol, Schiff bases, docking scores, dihydropteroate synthase.

« Previous
Graphical Abstract

[1]
Adedeji WA. The treasure called antibiotics. Ann Ib Postgrad Med 2016; 14(2): 56-7.
[PMID: 28337088]
[2]
Demain AL, Sanchez S. Microbial drug discovery: 80 years of progress. J Antibiot (Tokyo) 2009; 62(1): 5-16.
[http://dx.doi.org/10.1038/ja.2008.16] [PMID: 19132062]
[3]
Cirz RT, Chin JK, Andes DR, de Crécy-Lagard V, Craig WA, Romesberg FE. Inhibition of mutation and combating the evolution of antibiotic resistance. PLoS Biol 2005; 3(6)e176
[http://dx.doi.org/10.1371/journal.pbio.0030176] [PMID: 15869329]
[4]
Livermore DM. The need for new antibiotics. Clin Microbiol Infect 2004; 10(Suppl. 4): 1-9.
[http://dx.doi.org/10.1111/j.1465-0691.2004.1004.x] [PMID: 15522034]
[5]
Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health 2015; 109(7): 309-18.
[http://dx.doi.org/10.1179/2047773215Y.0000000030] [PMID: 26343252]
[6]
Blair JM, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJ. Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol 2015; 13(1): 42-51.
[http://dx.doi.org/10.1038/nrmicro3380] [PMID: 25435309]
[7]
Dever LA, Dermody TS. Mechanisms of bacterial resistance to antibiotics. Arch Intern Med 1991; 151(5): 886-95.
[http://dx.doi.org/10.1001/archinte.1991.00400050040010] [PMID: 2025137]
[8]
Fair RJ, Tor Y. Antibiotics and bacterial resistance in the 21st century. Perspect Medicin Chem 2014; 6: 25-64.
[http://dx.doi.org/10.4137/PMC.S14459] [PMID: 25232278]
[9]
Zinner SH. The search for new antimicrobials: why we need new options. Expert Rev Anti Infect Ther 2005; 3(6): 907-13.
[http://dx.doi.org/10.1586/14787210.3.6.907] [PMID: 16307503]
[10]
Meng XY, Zhang HX, Mezei M, Cui M. Molecular docking: a powerful approach for structure-based drug discovery. Curr Comput Aided Drug Des 2011; 7(2): 146-57.
[http://dx.doi.org/10.2174/157340911795677602] [PMID: 21534921]
[11]
Shoichet BK, McGovern SL, Wei B, Irwin JJ. Lead discovery using molecular docking. Curr Opin Chem Biol 2002; 6(4): 439-46.
[http://dx.doi.org/10.1016/S1367-5931(02)00339-3] [PMID: 12133718]
[12]
Schulz-Gasch T, Stahl M. Binding site characteristics in structure-based virtual screening: evaluation of current docking tools. J Mol Model 2003; 9(1): 47-57.
[http://dx.doi.org/10.1007/s00894-002-0112-y] [PMID: 12638011]
[13]
Dixit BC, Patel H, Desai DJ. Synthesis and application of new mordent and disperse azo dyes based on 2, 4-dihydroxybenzophenone. J Serb Chem Soc 2007; 72(2): 119-27.
[http://dx.doi.org/10.2298/JSC0702119D]
[14]
Chung KT. Azo dyes and human health: A review. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2016; 34(4): 233-61.
[http://dx.doi.org/10.1080/10590501.2016.1236602] [PMID: 27635691]
[15]
Chung KT, Stevens SE Jr, Cerniglia CE. The reduction of azo dyes by the intestinal microflora. Crit Rev Microbiol 1992; 18(3): 175-90.
[http://dx.doi.org/10.3109/10408419209114557] [PMID: 1554423]
[16]
Kaur H, Narasimhan B. Synthesis, Characterization, antimicrobial and antioxidant potential of diazenyl chalcones. Curr Top Med Chem 2018; 18(10): 844-56.
[http://dx.doi.org/10.2174/1568026618666180626095714] [PMID: 29943703]
[17]
Kaur H, Yadav S, Narasimhan B. Diazenyl derivatives and their complexes as anticancer agents. Anticancer Agents Med Chem 2016; 16(10): 1240-65.
[http://dx.doi.org/10.2174/1871520616666160607012042] [PMID: 27281366]
[18]
Kaur H, Narasimhan B. Antimicrobial activity of diazenyl derivatives: an update. Curr Top Med Chem 2018; 18(1): 3-21.
[http://dx.doi.org/10.2174/1568026618666180206093107] [PMID: 29412106]
[19]
Kaur H, Lim SM, Ramasamy K, Vasudevan M, Shah SA, Narasimhan B. Diazenyl schiff bases: synthesis, spectral analysis, antimicrobial studies and cytotoxic activity on human colorectal carcinoma cell line (HCT-116). Arab J Chem 2017.
[http://dx.doi.org/10.1016/j.arabjc.2017.05.004]
[20]
Kaur H, Desai SD, Singh J, Narasimhan B. Morpholine based diazenyl chalcones: Synthesis, antimicrobial screening and cytotoxicity study. Anticancer Agents Med Chem 2018; 18(15): 2193-205.
[http://dx.doi.org/10.2174/1871520618666180830152701] [PMID: 30173651]
[21]
Kaur H, Singh J, Narasimhan B. Synthesis of novel naphthol diazenyl scaffold based Schiff bases as potential antimicrobial and cytotoxic agents against human colorectal carcinoma cell line (HT-29). BMC Chemistry In Press
[http://dx.doi.org/10.1186/s13065-019-0558-y]
[22]
Alves MJ, Froufe HJ, Costa AF, et al. Docking studies in target proteins involved in antibacterial action mechanisms: extending the knowledge on standard antibiotics to antimicrobial mushroom compounds. Molecules 2014; 19(2): 1672-84.
[http://dx.doi.org/10.3390/molecules19021672] [PMID: 24481116]
[23]
Shaikh MH, Subhedar DD, Shingate BB, et al. Synthesis, biological evaluation and molecular docking of novel coumarin incorporated triazoles as antitubercular, antioxidant and antimicrobial agents. Med Chem Res 2016; 25(4): 790-804.
[http://dx.doi.org/10.1007/s00044-016-1519-9]
[24]
O’Shea R, Moser HE. Physicochemical properties of antibacterial compounds: implications for drug discovery. J Med Chem 2008; 51(10): 2871-8.
[http://dx.doi.org/10.1021/jm700967e] [PMID: 18260614]
[25]
Pawar VS, Lokwani DK, Bhandari SV, et al. Design, docking study and ADME prediction of Isatin derivatives as anti-HIV agents. Med Chem Res 2011; 20(3): 370-80.
[http://dx.doi.org/10.1007/s00044-010-9329-y]
[26]
Mouilleron S, Badet-Denisot MA, Golinelli-Pimpaneau B. Ordering of C-terminal loop and glutaminase domains of glucosamine-6-phosphate synthase promotes sugar ring opening and formation of the ammonia channel. J Mol Biol 2008; 377(4): 1174-85.
[http://dx.doi.org/10.1016/j.jmb.2008.01.077] [PMID: 18295797]
[27]
Sherer BA, Hull K, Green O, et al. Pyrrolamide DNA gyrase inhibitors: optimization of antibacterial activity and efficacy. Bioorg Med Chem Lett 2011; 21(24): 7416-20.
[http://dx.doi.org/10.1016/j.bmcl.2011.10.010] [PMID: 22041057]
[28]
Levy C, Minnis D, Derrick JP. Dihydropteroate synthase from Streptococcus pneumoniae: structure, ligand recognition and mechanism of sulfonamide resistance. Biochem J 2008; 412(2): 379-88.
[http://dx.doi.org/10.1042/BJ20071598] [PMID: 18321242]
[29]
Li X, Hilgers M, Cunningham M, et al. Structure-based design of new DHFR-based antibacterial agents: 7-aryl-2,4-diaminoquina- zolines. Bioorg Med Chem Lett 2011; 21(18): 5171-6.
[http://dx.doi.org/10.1016/j.bmcl.2011.07.059] [PMID: 21831637]
[30]
Bertrand JA, Auger G, Fanchon E, et al. Crystal structure of UDP-N-acetylmuramoyl-L-alanine: D-glutamate ligase from Escherichia coli. EMBO J 1997; 16(12): 3416-25.
[http://dx.doi.org/10.1093/emboj/16.12.3416] [PMID: 9218784]
[31]
Brvar M, Perdih A, Renko M, Anderluh G, Turk D, Solmajer T. Structure-based discovery of substituted 4,5′-bithiazoles as novel DNA gyrase inhibitors. J Med Chem 2012; 55(14): 6413-26.
[http://dx.doi.org/10.1021/jm300395d] [PMID: 22731783]
[32]
Hargrove TY, Friggeri L, Wawrzak Z, et al. Structural analyses of Candida albicans sterol 14α-demethylase complexed with azole drugs address the molecular basis of azole-mediated inhibition of fungal sterol biosynthesis. J Biol Chem 2017; 292(16): 6728-43.
[http://dx.doi.org/10.1074/jbc.M117.778308] [PMID: 28258218]
[33]
Podust LM, Poulos TL, Waterman MR. Crystal structure of cytochrome P450 14alpha -sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors. Proc Natl Acad Sci USA 2001; 98(6): 3068-73.
[http://dx.doi.org/10.1073/pnas.061562898] [PMID: 11248033]
[34]
Fang W, Robinson DA, Raimi OG, et al. N-myristoyltransferase is a cell wall target in Aspergillus fumigatus. ACS Chem Biol 2015; 10(6): 1425-34.
[http://dx.doi.org/10.1021/cb5008647] [PMID: 25706802]
[35]
Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 2000; 44(1): 235-49.
[http://dx.doi.org/10.1016/S1056-8719(00)00107-6] [PMID: 11274893]
[36]
Tsopelas F, Giaginis C, Tsantili-Kakoulidou A. Lipophilicity and biomimetic properties to support drug discovery. Expert Opin Drug Discov 2017; 12(9): 885-96.
[http://dx.doi.org/10.1080/17460441.2017.1344210] [PMID: 28644732]

Rights & Permissions Print Cite
Article Metrics
20
3
1
1
© 2024 Bentham Science Publishers | Privacy Policy